---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-004435"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T04:58:24.259633+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Viridian Therapeutics promotes Seth Harmon to CFO effective Jan 1, 2025

## Summary
- Seth Harmon, previously SVP of Finance and Accounting and Principal Financial Officer, appointed CFO effective Jan 1, 2025.
- New base salary of $480,000 and target bonus of 40% of base salary.
- Received equity awards: stock option with grant date value of $1,662,000 and RSUs with grant date value of $554,000.
- Harmon's prior roles include CFO of BioNTech US subsidiary and VP of Finance at Neon Therapeutics.

## SEC filing metadata
- accession: 0001193125-25-004435
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312525004435/0001193125-25-004435-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312525004435/d842633d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-004435
- JSON: https://secwatch.observer/filing/0001193125-25-004435.json
- Plain text: https://secwatch.observer/filing/0001193125-25-004435.txt

## Key facts
- Executive change
  Seth Harmon was appointed as Chief Financial Officer at Viridian Therapeutics, Inc.\DE.
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On January 7, 2025, the Board of Directors of Viridian Therapeutics, Inc. (the “Company”) appointed Seth Harmon to serve as the Chief Financial Officer of the Company effective as of January 1, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312525004435/0001193125-25-004435-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.